Time:
17:00-18:30 CET

Speaker: Ursula Theuretzbacher, CEFAIA (Austria)

Moderator: Prabhavathi Fernandes, Chair of GARDP’s Scientific Advisory Committee

In this webinar, Ursula Theuretzbacher discussed the following aspects of non-traditional antibacterial therapeutics:

  • Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline
  • These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation.
  • Some of these approaches require novel preclinical efficacy models to predict clinical outcome
  • Pathogen-specific or even patient-specific strategies dominate this field
  • A major challenge will be to show efficacy in clinical trials

For the Q&A session, Ursula was joined by Laura Piddock (GARDP).